All In Biotech

Drug Trial Radar · NCT06669117

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

A First-In-Human (FIH) Phase I/II Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors Including Non-small Cell Lung Cancer (NSCLC) Harboring Mesenchymal-Epithelial Transition (MET) Alterations

Last checked: Nov 19, 2026Latest source record: Jul 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Oct 22, 2024

Primary completion

Oct 21, 2030

Study completion Oct 1, 2032

Sponsor

Lead sponsor
Pierre Fabre MedicamentIndustry
Sponsor type
Industry
First posted
Nov 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.

Conditions

  • Solid Tumor
  • MET Alteration

Interventions

  • VERT-002Drug

    Route of Administration: Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: All parts: Incidence and severity of treatment emergent adverse events (TEAEs)/serious adverse events (SAEs), according to NCI-CTCAE v5.0 criteria.Time frame: Screening to Safety Follow-up (30 days post last dose)
  2. Tolerability: All parts: Incidence of TEAEs/SAEs leading to VERT-002 dose reduction, interruption or discontinuation.Time frame: From screening up to 13 months
  3. Part 1: Maximum Tolerated Dose (MTD): Incidence of Dose-Limiting Toxicities (DLTs)Time frame: From the start of trial treatment until end of Cycle 1 per dose level
  4. Part 1: Optimal Biologically Active Dose (OBD): Incidence on PK/PD and ORR (Objective Response Rate)Time frame: From the first VERT-002 intake up to 13 months
  5. Part2a: Preliminary activity assessment: ORR and cORR (Confirmed Objective Response Rate)Time frame: From the start of trial treatment up to 13 months
  6. Part2b: Recommended Phase 2 Dose (RP2D): Incidence on overall safety, PK, PDs and cORRTime frame: From the start of trial treatment up to 13 months

Locations

19 sites in 9 countries. Site status is shown where the registry gives one.

  • Georgetown Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia · Recruiting

  • Gabrail Cancer Research Center

    Canton, Ohio · Recruiting

  • Sarah Cannon Research Institute Oncology Partners

    Nashville, Tennessee · Recruiting

  • Institut Jules Bordet

    Anderlecht, Belgium · Recruiting

  • APHP de Marseille - Hôpital Nord

    Marseille, France · Recruiting

  • Institut de Cancerologie de Ouest (ICO) - Saint-Herblain

    Saint-Herblain, France · Recruiting

  • Institut Universitaire du Cancer de Toulouse - Oncopole

    Toulouse, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Universitaet zu Koeln - Centrum fuer Integrierte Onkologie (CIO)

    Cologne, Germany · Recruiting

  • Universitätsklinikum Carl Gustav Carus Dresden

    Dresden, Germany · Recruiting

  • Azienda Ospedaliero - Universitaria San Luigi Gonzaga

    Orbassano, Italy · Recruiting

  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis

    Amsterdam, Netherlands · Recruiting

  • Yonsei University College of Medicine

    Seoul, South Korea · Recruiting

  • Asan Medical Center (AMC)

    Seoul, South Korea · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

  • Taipei Medical University Hospital

    Taipei, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.